Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TET3 | O43151 | 3/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.34 |
| ▸ | FBXL19 | Q6PCT2 | 3/20 | 0.34 |
| ▸ | CXXC5 | Q7LFL8 | 3/20 | 0.34 |
| ▸ | KDM2B | Q8NHM5 | 3/20 | 0.34 |
| ▸ | CXXC4 | Q9H2H0 | 3/20 | 0.34 |
| ▸ | KDM2A | Q9Y2K7 | 3/20 | 0.34 |
| ▸ | TET1 | Q8NFU7 | 2/20 | 0.34 |
| ▸ | TEAD1 | P28347 | 7/20 | 0.33 |
| ▸ | JAK3 | P52333 | 7/20 | 0.33 |
| ▸ | BTK | Q06187 | 3/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22970007 | 0.79 | CHRM1 (0.42) | JAK3BTK | |
| SCHEMBL20334409 | 0.79 | JAK3 (0.33) | TET3KMT2AFBXL19CXXC5KDM2B | |
| SCHEMBL19909714 | 0.79 | CHRM1 (0.42) | JAK3BTK | |
| SCHEMBL22704583 | 0.79 | CHRM1 (0.42) | JAK3BTK | |
| SCHEMBL23323368 | 0.79 | JAK3 (0.35) | TEAD1JAK3BTK | |
| SCHEMBL21741246 | 0.77 | TEAD1 (0.36) | TEAD1JAK3BTK | |
| SCHEMBL23278104 | 0.77 | TEAD1 (0.34) | TEAD1JAK3BTK | |
| SCHEMBL20314874 | 0.77 | TEAD1 (0.36) | TET3KMT2AFBXL19CXXC5KDM2B | |
| SCHEMBL20161816 | 0.76 | CYP1A2 (0.36) | TEAD1JAK3BTK | |
| SCHEMBL20326344 | 0.76 | JAK3 (0.33) | TEAD1JAK3BTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3558955-B1 | BENZISOTHIAZOLE, ISOTHIAZOLO[3,4-B]PYRIDINE, QUINAZOLINE, PHTHALAZINE, PYRIDO[2,3-D]PYRIDAZINE AND PYRIDO[2,3-D]PYRIMIDINE DERIVATIVES AS KRAS G12C INHIBITORS FOR TREATING LUNG, PANCREATIC OR COLORECTAL CANCER | AMGEN INC (US) | 2021-08-11 | — | — | EP | disclosed |